Navigation Links
CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Date:11/7/2007

Two Large Phase III Trials Confirm Robust Efficacy of CIMZIA

BOSTON, Nov. 7 /PRNewswire/ -- UCB announced today the results of new Phase III data from the RAPID 1 and 2 studies presented at the American College of Rheumatology Annual Scientific Meeting (ACR), which show CIMZIA(R) (certolizumab pegol), the first and only PEGylated Fc-free anti-TNF (Tumor Necrosis Factor), given with methotrexate, is significantly more effective than methotrexate alone for the inhibition of progression of structural joint damage in patients with active rheumatoid arthritis (RA). Also, CIMZIA combined with methotrexate was shown to significantly reduce the signs and symptoms of active RA compared with methotrexate alone for up to one year.

The RAPID 1 data show that CIMZIA, given every two weeks with methotrexate, is significantly more effective for the inhibition of the progression of structural joint damage compared with placebo plus methotrexate at both six and 12 months, as measured in change from mTSS(b) at baseline. Data from RAPID 2 confirm these results, showing that CIMZIA in combination with methotrexate is significantly more effective in inhibiting the progression of structural joint damage compared with placebo plus methotrexate at six months.

"These findings suggest that treatment with certolizumab pegol plus methotrexate can significantly inhibit structural joint damage, which is important for patients who do not respond effectively to methotrexate," explained Edward Keystone, M.D., Rheumatology Department at the University of Toronto. "The data show that certolizumab pegol may lessen debilitating damage and suggest that it has the potential to become an important therapeutic option for patients with RA."

In addition, another study demonstrated the efficacy of CIMZIA in the treatment of the signs and symptoms of RA as a monotherapy, administered every four weeks. "This potential flexibility in dosing could be important for patients," co
'/>"/>

SOURCE UCB
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
7. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
8. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 1, 2011 Serina Therapeutics, Inc. President and CEO Randall ... a $9.5 million financing round to advance its lead oncology ... early 2012. "We are pleased to report to ... round that was launched in late 2010. This is a ...
... 2011 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... officer will present a corporate overview at the Goldman Sachs ... p.m. PT.  The conference will be held at the Terranea ... webcast and audio archive of the presentation will be available ...
Cached Medicine Technology:Serina Therapeutics, Inc. Closes $9.5 Million Financing Round 2
(Date:4/23/2014)... Washington, April 21, 2014 Five for-profit and ... of $1.25 million in Proof of Concept grants ... ideas into commercial products, the Life Sciences Discovery ... $300,000 Entrepreneur Mentoring Program grant to the Washington ... statewide advisory network to train the next generation ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/22/2014)... school sport in the United States with 1 million ... the Center for Injury Research and Policy at Nationwide ... the occurrence and distribution patterns of basketball-related injuries treated ... setting among adolescents and teens. , The study, published ... examined data relating to adolescents 13-19 years of age ...
(Date:4/22/2014)... care for low-income patients may ease the financial ... improving patient health, researchers have concluded. , A ... that avoid costs associated with insurance administration can ... rates and emergency room visits, according to Mark ... , The researchers estimated that the major hospital ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... unlikely to be caused by a decrease in mammography screening, ... Journal of the National Cancer Institute . It is ... , There has been a recent, rapid decline in ... Initiative study found that hormone therapy was associated with an ...
... B: apo A-I ratio is not a better predictor ... that include total cholesterol and HDL-C, according to a ... Current risk-prediction instruments and guidelines for coronary heart disease ... (LDL-C), total cholesterol, or both for CHD risk assessment. ...
... can diagnose venous thromboembolic disease (VTED) in cancer patients ... the thorax, abdomen, and pelvis which are regularly done ... according to a recent study conducted by radiologists at ... , Venous thromboembolic disease can be fatal if left ...
... warfarin) and antiplatelet drugs (e.g., acetylsalicylic acid) are ... diseases. In this study, Joseph Delaney MSc, Dr. ... in 4,028 cases with a diagnosis of gastrointestinal ... Kingdom. They documented a 46-fold increase in the ...
... Spirometry testing is a widely accepted and encouraged ... new research shows that it is not used nearly ... CHEST, the peer-reviewed journal of the American College of ... patients with a COPD diagnosis ever received spirometry testing. ...
... in a nursing home or take medication to lower ... following hospitalization for heatstroke, according to a study posted ... issue of Archives of Internal Medicine, one of the ... online today found that being confined to bed, not ...
Cached Medicine News:Health News:Drop in breast cancer incidence linked to hormone use, not mammograms 2Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Study says COPD testing is not measuring up 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 3
... Long Instrument for applications in ... Plus Long Instrument with 150mm ... endoscopic entry device that has ... is used to establish entry ...
... The Autosuture™ Blunt Tip Trocar consists ... handle and a valve body assembly. , ... internal flapper valve and seal to prevent ... withdrawn. The Autosuture™ Blunt Tip Trocar includes ...
... components are supplied sterile. , ,The Step™ ... sterile in 2/3, 5, 7/8, 10 and 12 ... They are used in conjunction with the Step™ ... Expandable Sleeve. The 5, 7/8, 10 and 12 ...
... The Step™ and Mini Step™ device components are ... Step™ Single Use System is supplied sterile in ... packaged in various configurations and combinations. They are ... Access needle and the Step™ radially Expandable Sleeve. ...
Medicine Products: